Mandana Kamgar, MD, MPH

Publications

• Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes.

  (Beltran Ponce SE, Small CJ, Ahmad T, Patel K, Tsai S, Kamgar M, George B, Kharofa JR, Saeed H, Dua KS, Clarke C, Aldakkak M, Evans DB, Christians K, Paulson ES, Erickson B, Hall WA.) Pract Radiat Oncol. 2024 Aug 23 PMID: 39182645 08/26/2024

• Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.

  (George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S.) Gastroenterology. 2024 May;166(5):859-871.e3 PMID: 38280684 SCOPUS ID: 2-s2.0-85188891214 01/28/2024

• Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer

  (Jameson GS, Hosein PJ, Pierce E, Kamgar M, Gordon MS, Snyder C, Roe DJ, Wertheim BC, Davey M, Barrett MT, Von Hoff DD, Borazanci E.) Cancer Medicine. June 2024;13(12) SCOPUS ID: 2-s2.0-85196660360 06/01/2024

• Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series.

  (Mehdi M, Szabo A, Shreenivas A, Thomas JP, Tsai S, Christians KK, Evans DB, Clarke CN, Hall WA, Erickson B, Ahmed G, Thapa B, McFall T, George B, Kurzrock R, Kamgar M.) Ther Adv Med Oncol. 2024;16:17588359241253113 PMID: 38770091 PMCID: PMC11104030 SCOPUS ID: 2-s2.0-85193752803 05/21/2024

• Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review.

  (Mody J, Kamgar M.) Case Rep Oncol. 2024;17(1):399-406 PMID: 38435447 PMCID: PMC10907001 03/04/2024

• Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

  (de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans DB, Christians KK, Clarke CN, George B, Shreenivas A, Kamgar M, Chakrabarti S, Dua KS, Khan AH, Madhavan S, Erickson BA, Hall WA.) Cancer Med. 2024 Jan;13(1):e6582 PMID: 38140796 PMCID: PMC10807686 SCOPUS ID: 2-s2.0-85180644976 12/23/2023

• Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer.

  (Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S.) Ann Surg. 2023 Dec 01;278(6):e1224-e1231 PMID: 37078282 SCOPUS ID: 2-s2.0-85176508848 04/20/2023

• Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.

  (Thalji SZ, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Chisholm P, Kulkarni N, Doucette S, Evans DB, Tsai S.) J Surg Oncol. 2023 Jul;128(1):41-50 PMID: 36960919 SCOPUS ID: 2-s2.0-85152449940 03/25/2023

• Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.

  (Sreeram K, Seaton R, Greenwald MK, Kamgar M, Assad H, Baird T, Schwartz AG, Ruterbusch J, Simon MS.) Cancer Causes Control. 2023 May;34(5):459-468 PMID: 36934365 PMCID: PMC10373434 SCOPUS ID: 2-s2.0-85150302312 03/20/2023

• CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

  (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3013-3021 PMID: 36788189 SCOPUS ID: 2-s2.0-85147934173 02/15/2023

• Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort

  (Sreeram K, Seaton R, Greenwald MK, Kamgar M, Assad H, Baird T, Schwartz AG, Ruterbusch J, Simon MS.) Cancer Causes and Control. May 2023;34(5):459-468 SCOPUS ID: 2-s2.0-85150302312 05/01/2023

• Comprehensive genomic profiling: Does timing matter?

  (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B.) Front Oncol. 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 03/04/2023